Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-04-15 Sale |
2025-04-17 5:41 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
100,000 | $0 | $0 | 594,930 (Direct) |
View |
| 2025-03-26 Purchase |
2025-03-28 5:36 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director |
1,135 | $22.49 | $25,521 | 6,814,569 (Indirect) |
View |
| 2025-03-26 Sale |
2025-03-28 5:18 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
16,539 | $0 | $0 | 60,539 (Direct) |
View |
| 2025-03-26 Sale |
2025-03-28 5:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer |
12,258 | $0 | $0 | 428,835 (Direct) |
View |
| 2025-03-17 Sale |
2025-03-19 5:29 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
100,000 | $0 | $0 | 742,181 (Direct) |
View |
| 2025-03-04 Purchase |
2025-03-06 5:32 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director |
4,005 | $21.02 | $84,203 | 6,813,434 (Indirect) |
View |
| 2025-03-04 Sale |
2025-03-05 6:10 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer |
150,000 | $20.37 | $3,055,500 | 33,073 (Direct) |
View |
| 2025-02-18 Sale |
2025-02-20 5:24 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
100,000 | $0 | $0 | 305,508 (Direct) |
View |
| 2025-01-29 Sale |
2025-01-31 5:00 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
70,441 | $0 | $0 | 509,868 (Direct) |
View |
| 2025-01-27 Sale |
2025-01-29 5:25 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer |
61,883 | $0 | $0 | 1,578,528 (Direct) |
View |
| 2025-01-27 Sale |
2025-01-29 5:16 pm |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
129,559 | $0 | $0 | 662,557 (Direct) |
View |
| 2024-12-30 Sale |
2025-01-02 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
29,846 | $25.54 | $762,174 | 10,656,172 (Indirect) |
View |
| 2024-12-26 Sale |
2024-12-30 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
74,910 | $25.98 | $1,945,918 | 10,686,018 (Indirect) |
View |
| 2024-12-20 Sale |
2024-12-26 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
91,068 | $25.58 | $2,329,520 | 10,760,928 (Indirect) |
View |
| 2024-12-18 Sale |
2024-12-20 4:25 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
157,234 | $25.86 | $4,066,714 | 10,851,996 (Indirect) |
View |
| 2024-12-16 Sale |
2024-12-18 4:15 pm |
NewAmsterdam Pharma Co N.V. | NAMS | ForGrowth NAP B.V. Forbion Capital Fund IV Cooperatief U.A. Forbion IV Management B.V. Forbion Growth Opportunities Fund I Cooperatief U.A. Forbion Growth Management B.V. 10% Owner |
115,480 | $25.95 | $2,996,156 | 11,009,230 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-04-15 Exercise |
2025-04-17 5:41 pm |
N/A 2032-11-22 |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
100,000 | $0 | 594,930 (Direct) |
View |
| 2025-04-15 Exercise |
2025-04-17 5:41 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
100,000 | $10 | 594,930 (Direct) |
View |
| 2025-04-15 Option Award |
2025-04-17 5:36 pm |
N/A 2035-04-15 |
NewAmsterdam Pharma Co N.V. | NAMS | Gulfo Adele M. Director |
61,560 | $0 | 61,560 (Direct) |
View |
| 2025-03-26 Exercise |
2025-03-28 5:29 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer |
8,269 | $0 | 31,538 (Direct) |
View |
| 2025-03-26 Option Award |
2025-03-28 5:29 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer |
8,269 | $0 | 31,538 (Direct) |
View |
| 2025-03-26 Exercise |
2025-03-28 5:24 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director |
3,102 | $0 | 13,576 (Direct) |
View |
| 2025-03-26 Option Award |
2025-03-28 5:24 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director |
3,308 | $0 | 13,576 (Direct) |
View |
| 2025-03-26 Exercise |
2025-03-28 5:20 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer |
45,481 | $0 | 294,264 (Direct) |
View |
| 2025-03-26 Option Award |
2025-03-28 5:20 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer |
64,783 | $0 | 294,264 (Direct) |
View |
| 2025-03-26 Exercise |
2025-03-28 5:18 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
16,539 | $0 | 60,539 (Direct) |
View |
| 2025-03-26 Option Award |
2025-03-28 5:18 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
16,539 | $0 | 60,539 (Direct) |
View |
| 2025-03-26 Exercise |
2025-03-28 5:15 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer |
38,394 | $0 | 428,835 (Direct) |
View |
| 2025-03-26 Option Award |
2025-03-28 5:15 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer |
69,386 | $0 | 428,835 (Direct) |
View |
| 2025-03-24 Exercise |
2025-03-26 4:27 pm |
N/A 2031-07-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer |
150,000 | $0 | 970,229 (Indirect) |
View |
| 2025-03-17 Exercise |
2025-03-19 5:29 pm |
N/A 2031-07-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
100,000 | $0 | 742,181 (Direct) |
View |
| 2025-03-17 Exercise |
2025-03-19 5:29 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
11,888 | $10 | 742,181 (Direct) |
View |
| 2025-03-04 Exercise |
2025-03-05 6:10 pm |
N/A 2031-07-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer |
150,000 | $0 | 33,073 (Direct) |
View |
| 2025-02-18 Exercise |
2025-02-20 5:24 pm |
N/A 2031-07-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
100,000 | $0 | 305,508 (Direct) |
View |
| 2025-01-29 Exercise |
2025-01-31 5:00 pm |
N/A 2031-07-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
70,441 | $0 | 509,868 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 5:25 pm |
N/A 2033-11-01 |
NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer |
61,883 | $0 | 1,578,528 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 5:25 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer |
61,883 | $9.26 | 1,578,528 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 5:16 pm |
N/A 2031-07-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
129,559 | $0 | 662,557 (Direct) |
View |
| 2025-01-06 Option Award |
2025-01-08 6:09 pm |
N/A 2035-01-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Smither John W Director |
39,460 | $0 | 39,460 (Direct) |
View |
| 2025-01-06 Option Award |
2025-01-08 6:08 pm |
N/A 2035-01-06 |
NewAmsterdam Pharma Co N.V. | NAMS | McKenna Mark C. Director |
39,460 | $0 | 39,460 (Direct) |
View |
| 2025-01-06 Option Award |
2025-01-08 6:03 pm |
N/A 2035-01-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Lewis William Director |
39,460 | $0 | 39,460 (Direct) |
View |
| 2025-01-06 Option Award |
2025-01-08 5:58 pm |
N/A 2035-01-06 |
NewAmsterdam Pharma Co N.V. | NAMS | van der Kamp Hilde Johanna Director |
39,460 | $0 | 39,460 (Direct) |
View |
| 2025-01-06 Option Award |
2025-01-08 5:57 pm |
N/A 2035-01-06 |
NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director |
39,460 | $0 | 64,338 (Direct) |
View |
| 2025-01-07 Option Award |
2025-01-07 5:21 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer |
15,000 | $0 | 15,000 (Direct) |
View |
| 2025-01-06 Option Award |
2025-01-07 5:21 pm |
N/A 2035-01-06 |
NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer |
793,996 | $0 | 793,996 (Direct) |
View |
| 2025-01-07 Option Award |
2025-01-07 5:21 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer |
34,000 | $0 | 34,000 (Direct) |
View |
| 2025-01-07 Option Award |
2025-01-07 5:15 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere Chief Business Officer |
14,000 | $0 | 15,104 (Direct) |
View |
| 2025-01-07 Option Award |
2025-01-07 5:12 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | JONES WILLIAM A JR Chief Commercial Officer |
43,000 | $0 | 43,000 (Direct) |
View |
| 2025-01-07 Option Award |
2025-01-07 5:10 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
44,000 | $0 | 44,000 (Direct) |
View |
| 2025-01-07 Option Award |
2025-01-07 5:08 pm |
N/A N/A |
NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer |
38,000 | $0 | 38,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:57 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer |
250,000 | $0 | 250,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:56 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer |
80,000 | $0 | 80,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:54 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere Chief Business Officer |
100,000 | $0 | 100,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:53 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer |
220,000 | $0 | 220,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:51 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | JONES WILLIAM A JR Chief Commercial Officer |
200,000 | $0 | 200,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 5:48 pm |
N/A 2035-01-02 |
NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer |
200,000 | $0 | 200,000 (Direct) |
View |